ArticleChinese medicine2025
Identification of salvianolic acid A as an ADP receptor-selective and Gq/IP
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAntiplatelet therapy is crucial for preventing and treating cardio-cerebrovascular diseases. However, adverse events related to thrombosis or bleeding have been reported in instances of treatment with glycoprotein IIb/IIIa antagonists. It is anticipated that developing new selective platelet inhibitors with high anti-thrombotic efficiency and minimal hemorrhagic side effects is feasible. Qishen Yiqi Dripping Pill (QSYQ), an approved drug for ischemic heart disease, was studied for its anti-thrombotic effects. METHODS AND
resultsEmploying a microplate-based platelet aggregation assay, we systematically evaluated QSYQ and its medicinal components, chemical fractions, and compounds from the active fractions, identifying Salvianolic acid A (SAA) as one of the major active components for platelet inhibition. Our findings revealed that SAA decreased platelet [Ca
conclusionThis study identified SAA as one of the pharmacologically active anti-platelet components in QSYQ and revealed that its mechanism of action operates via the G
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.